TABLE 2.

% Survival versus seroconversion rate as determined based on anti-F1, anti-V, and anti-F1-V responses

Group	Formulation type	No. of doses	% Survival	% Seroconversiona
				Anti-F1	Anti-V	Anti-F1-V
1	IM SFD/AL	2	70	100	100	100
2	IM liquid/AL	2	80	100	100	100
3	IM liquid	2	30	40	90	80
4	ID SFD/AL	2	90	100	100	100
5	ID liquid/AL	2	100	100	100	100
6	ID liquid	2	10	30	60	60
7	IN SFD/LPS	2	33	44	100	100
8	IN liquid/LPS	2	50	50	100	100
9	IN liquid	2	0	0	70	70
10	IN SFD/LPS	3	80	80	100	100
11	IN liquid/LPS	3	67	100	100	100
12	IN liquid	3	10	20	80	80
13	Naive	-	10	0	0	0

^aPercent seroconversion was based on a serum IgG titer of ≥50. AL, Alhydrogel.